



Prenetics Completes \$72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8's Path to \$100 Million ARR

October 7, 2025

- *Strengthens Balance Sheet with Over \$60 Million in Cash¹, Excluding Bitcoin Treasury*
- *David Beckham Co-Founded IM8 on Track to Achieve \$100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement Brands in the History of the Industry*
- *Bitcoin Treasury Grows to 255 BTC with 1 BTC Per Day Purchase Strategy Since August, NAV now at \$31.6 Million, with an unrealized profit of \$3.86 Million*

CHARLOTTE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the official completion of its divestment of ACT Genomics Co., Ltd. ("ACT") to Delta Electronics, Inc. (TWSE:2308). This transaction marks a final step in Prenetics' strategic exit from the clinical diagnostics sector, enabling the company to dedicate its resources and attention to its rapidly expanding consumer health initiatives.

The divestment significantly strengthens Prenetics' financial position. Based on its ownership percentage, Prenetics has received \$39.9 million in cash from the \$72 million transaction, with an additional approximately \$6.3 million held in escrow to be distributed over the next 18 months, bringing Prenetics' total proceeds to \$46 million. This brings Prenetics' total cash reserves to over \$60 million¹, excluding its Bitcoin treasury, while maintaining a debt-free balance sheet. This strong financial foundation provides ample capital to fuel the growth of its flagship consumer health brand, IM8.

The strategic shift allows Prenetics to fully capitalize on the remarkable momentum of IM8, which is on pace to achieve an annualized revenue run-rate (ARR) of \$100 million within its first 12 months of launch. This trajectory positions IM8 as one of the fastest-growing supplement brands in the history of the industry, demonstrating strong market demand and execution.

In addition to its robust cash position, Prenetics also provided an update on its Bitcoin treasury strategy. The company now holds 255.4 BTC, with a current portfolio value of \$31.6 million, representing a total investment of \$27.8 million at an average cost of \$108,972 per Bitcoin. This strategic allocation has generated an unrealized profit of \$3.86 million, delivering a 13.9% return on the Bitcoin treasury investment, which initiated on June 16, 2025. Since August 1, 2025, Prenetics has implemented a disciplined approach of purchasing 1 BTC daily, with all holdings securely custodied at Kraken. In full transparency, all Bitcoin purchases and comprehensive analytics on the company's BTC strategy are publicly available at www.prenetics.com/btc.

"The completion of the ACT divestment represents a pivotal transformation for Prenetics," said Danny Yeung, CEO and Co-Founder of Prenetics. "We have successfully streamlined our operations to focus entirely on our high-growth consumer health business, while building a very healthy balance sheet. With over \$60 million in cash, zero debt, and our strategic Bitcoin treasury, we are exceptionally well-positioned to capitalize on IM8's extraordinary momentum. Our daily Bitcoin accumulation strategy reflects our long-term conviction in digital assets as a treasury reserve, and we're excited to share this journey transparently with our investors and stakeholders."

About Prenetics

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World's fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial \$20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. To learn more please visit www.prenetics.com and www.IM8health.com.

Investor Relations Contact:

investors@prenetics.com

PRE@mzgroup.us

Angela Cheung

Investor Relations / Corporate Finance

angela.hm.cheung@prenetics.com

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Prenetics may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Prenetics' beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not to the following: the Company's ability to execute its strategies, manage its growth, and achieve and maintain profitability; the Company's ability to develop and commercialize its products and services; the Company's ability to maintain and enhance its brand; the Company's ability to compete effectively; the Company's ability to continue to develop and maintain relationships with its partners and customers; the Company's ability to protect its intellectual property; the Company's ability to comply with applicable laws and regulations; and the Company's ability to obtain additional financing. Further

information regarding these and other risks is included in Prenetics' filings with the SEC. All information provided in this press release is as of the date of this press release, and Prenetics does not undertake any duty to update such information, except as required under applicable law.

1. Total cash reserves assuming full settlement of transaction proceeds